Urteste publishes first peer-reviewed Panuri paper

Urteste said July 22, 2026, that its first peer-reviewed paper on the Panuri urine test for pancreatic cancer has been published in Diagnostics. The paper adds scientific validation to the company’s European clinical program, which is still underway and not yet CE-marked.

Why it matters: - The publication gives Urteste’s Panuri program its first peer-reviewed scientific validation. - Panuri is being developed as a non-invasive urine test for early pancreatic cancer detection, a use case with high clinical need because pancreatic cancer is often found late. - The paper may help support investor, scientific, and regulatory confidence as Urteste advances European clinical testing.

What happened: - Urteste S.A. announced the publication of the first peer-reviewed article describing the analytical validation of Panuri, its investigational urine-based test for pancreatic cancer. - The paper, titled "Development and Analytical Evaluation of Urine-Based Test for Detection of Pancreatic Cancer," appeared in Diagnostics. - Urteste said the publication is a milestone for the company and supports the ongoing clinical development of Panuri. - The company also said management will attend the ADLM 2026 Annual Scientific Meeting & Clinical Lab Expo in Anaheim, California, July 26–30, 2026.

The details: - Panuri is an investigational in vitro diagnostic device that has not yet obtained CE marking. - The test is currently undergoing a multicenter clinical performance evaluation study across Europe under the IVDR framework. - Panuri is designed to support diagnosis of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. - The technology measures disease-associated proteolytic activity in urine using proprietary synthetic peptides. - Urteste said the analytical development showed 89% analytical sensitivity and 75% analytical specificity. - Urteste said the assay also demonstrated high analytical precision, including repeatability, within-laboratory precision and inter-laboratory reproducibility, with coefficients of variation below 10%. - The article is available in Diagnostics (2026) at the published study. - Urteste currently has 13 prototypes covering cancers of the breast, brain, stomach, bile ducts, ovaries, bladder, endometrium, kidneys, colon, lungs, liver, pancreas and prostate. - Urteste said those cancers together account for nearly 70% of all cancer-related deaths worldwide. - The company’s broader technology detects cancers by measuring enzyme activity in urine and looking for resulting changes in urine color intensity.

Between the lines: - The peer-reviewed paper strengthens the scientific case for Panuri before completion of the larger clinical study. - Urteste is pairing publication of early data with a business-development push at ADLM, which suggests the company wants both validation and partnership interest at the same time. - The results are promising for an early-stage diagnostic program, but the test still needs regulatory progress and clinical evidence before broader use.

What's next: - Urteste is continuing its prospective multicenter clinical performance study in patients undergoing diagnostic work-up for suspected pancreatic cancer. - The study is being run at 30 clinical sites across Poland, Italy and Hungary. - The company expects about 550 evaluable participants. - Study results will support the European regulatory process for Panuri under the IVDR. - Urteste plans to present progress on the Panuri program and discuss the publication and clinical study at ADLM 2026.

The bottom line: - Urteste has moved Panuri from analytical validation into peer-reviewed publication, but the test still needs clinical and regulatory milestones before it can reach the market.